Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 185

Results For "company"

4867 News Found

Strides receives USFDA approval for Sevelamer Carbonate Tablets
Drug Approval | May 11, 2024

Strides receives USFDA approval for Sevelamer Carbonate Tablets

Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment


OMRON Healthcare India and AliveCor partner to improve heart healthcare in India
Healthcare | May 11, 2024

OMRON Healthcare India and AliveCor partner to improve heart healthcare in India

These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more


Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr
News | May 11, 2024

Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr

Ami Organics has reported total income of Rs. 226.30 crores during the period ended March 31, 2024


Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
News | May 11, 2024

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024


Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr
News | May 11, 2024

Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr

Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024


Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr
News | May 10, 2024

Abbott India posts Q4 FY24 PAT at Rs. 287.06 Cr

The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024


Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
News | May 10, 2024

Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr

The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024


Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
News | May 10, 2024

Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr

The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024


Cipla receives 1 observation from USFDA for Kurkumbh facility
Drug Approval | May 10, 2024

Cipla receives 1 observation from USFDA for Kurkumbh facility

The company is committed to address this observation comprehensively within stipulated time


Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Drug Approval | May 10, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25